Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash from Operations: 2023-2025

Historic Cash from Operations for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to -$40.5 million.

  • Immunome's Cash from Operations fell 18.56% to -$40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$185.0 million, marking a year-over-year decrease of 114.66%. This contributed to the annual value of -$110.8 million for FY2024, which is 1363.98% down from last year.
  • According to the latest figures from Q3 2025, Immunome's Cash from Operations is -$40.5 million, which was up 18.00% from -$49.4 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Cash from Operations ranged from a high of $24.2 million in Q1 2023 and a low of -$53.1 million during Q1 2025.
  • In the last 3 years, Immunome's Cash from Operations had a median value of -$23.4 million in 2024 and averaged -$23.8 million.
  • Data for Immunome's Cash from Operations shows a maximum YoY crashed of 374.98% (in 2025) over the last 5 years.
  • Over the past 3 years, Immunome's Cash from Operations (Quarterly) stood at -$17.5 million in 2023, then crashed by 140.91% to -$42.1 million in 2024, then dropped by 18.56% to -$40.5 million in 2025.
  • Its Cash from Operations was -$40.5 million in Q3 2025, compared to -$49.4 million in Q2 2025 and -$53.1 million in Q1 2025.